Pfizer targets five internet sites for selling an unapproved copy of Pfizer's top selling cholesterol medicine, Lipitor

NewsGuard 100/100 Score
Pfizer has filed lawsuits against the operators of five internet sites for selling an unapproved copy of Pfizer's top selling cholesterol medicine, Lipitor, the company said today.

The suits were filed in U.S. district courts in Delaware and Connecticut against Generic Lipitors, Online Rx DrugStore, WorldMedsRX, B. M. International, and Offshore Pharma.

Pfizer said the sites market a product called "Storvas," which is advertised as being manufactured by Ranbaxy Pharmaceuticals Inc. of India . The lawsuits seek injunctions against further sales of "Storvas" and claim damages for infringement of Pfizer's patent and trademark rights for Lipitor. The complaints also seek to remove references to Lipitor in advertising materials and to eliminate computer links that misdirect patients to an illegal, unapproved product.

Pfizer filed a similar suit on April 12 against in U.S. District Court in Delaware. The company noted that the internet provides easy access to websites that sell unapproved or counterfeit pharmaceutical products that could put patient health at risk.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel cholesterol removal strategy shows potential benefits post-heart attack